GlassScriptPhysician profile
Allison Rose Cosgrove
NPI 1588403323
$3,732.85
in general payments reported to CMS, 2019-2025
44 companies · $2,952 in 2025
The $2,952 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $781 · 2025: $2,952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,634 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,633.85 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $478.81 | 2024-2025 | Enhertu, Injectafer, Datroway |
| Janssen Biotech, INC. | $354.44 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Novartis Pharmaceuticals Corporation | $309.29 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $256.35 | 2024-2025 | Imfinzi, Calquence, Enhertu |
| Incyte Corporation | $163.90 | 2025 | Jakafi, Zynyz, Monjuvi |
| Regeneron Healthcare Solutions, INC. | $160.52 | 2024-2025 | Libtayo, Lynozyfic |
| Pfizer INC. | $152.72 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $147.52 | 2024-2025 | Keytruda, Lynparza, Reblozyl |
| Abbvie INC. | $118.25 | 2025 | |
| Pharmacosmos Therapeutics INC. | $109.81 | 2024-2025 | Monoferric, Cosela |
| Glaxosmithkline, LLC. | $105.73 | 2025 | Ojjaara, Zejula, Jemperli |
| Lilly USA, LLC | $97.56 | 2024-2025 | Jaypirca, Verzenio |
| Iovance Biotherapeutics, INC. | $83.68 | 2025 | Amtagvi |
| Legend Biotech USA INC. | $81.84 | 2024-2025 | Carvykti |
| Jazz Pharmaceuticals INC. | $80.71 | 2024-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $65.73 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $53.08 | 2025 | Onivyde, Somatuline Depot |
| E.R. Squibb & Sons, L.L.C. | $51.52 | 2025 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $50.79 | 2024-2025 | Ninlaro |
| Bayer Healthcare Pharmaceuticals INC. | $50.09 | 2024-2025 | |
| Geron Corporation | $48.40 | 2025 | Rytelo |
| Novocure INC. | $47.70 | 2025 | Optune Gio, Optune Lua (Novottf-200t) |
| Sobi, INC | $47.16 | 2024-2025 | |
| Genmab U.S., INC. | $47.12 | 2025 | Epkinly |
| Azurity Pharmaceuticals, INC. | $46.31 | 2025 | Danziten |
| Tempus Ai, INC | $42.96 | 2025 | Xt Cdx |
| Array Biopharma INC | $41.60 | 2025 | Mektovi, Braftovi, Lorbrena |
| Puma Biotechnology, INC. | $37.64 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.51 | 2024-2025 | Gilotrif |
| Genentech USA, INC. | $32.55 | 2025 | Itovebi, Venclexta |
| Agios Pharmaceuticals, INC. | $32.36 | 2025 | Pyrukynd |
| Gilead Sciences, INC. | $31.97 | 2025 | Trodelvy |
| Stemline Therapeutics INC. | $30.70 | 2025 | Orserdu |
| Kite Pharma, INC. | $27.44 | 2025 | Yescarta |
| Caris Mpi, INC. | $26.27 | 2025 | Mi Cancer Seek |
| Taiho Oncology, INC. | $25.58 | 2025 | |
| Beone Medicines USA, INC. | $24.91 | 2025 | Tevimbra |
| Fennec Pharmaceuticals, INC. | $24.56 | 2025 | Fyarro |
| Aveo Pharmaceuticals, INC. | $22.71 | 2025 | |
| Fresenius Kabi USA, LLC | $18.46 | 2025 | |
| Servier Pharmaceuticals LLC | $18.41 | 2024 | |
| Amneal Pharmaceuticals LLC | $17.14 | 2025 | Alymsys |
| Janssen Pharmaceuticals, INC | $16.18 | 2024 | Xarelto |
| Eisai INC. | $14.87 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Cosgrove listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.